Piper Sandler raises argenx stock price target to $820 on Vyvgart success

Investing.com - Piper Sandler has raised its price target on argenx SE (NASDAQ:ARGX) to $820.00 from $750.00 while maintaining an Overweight rating following positive clinical trial results. The company, currently valued at $43.1 billion, has demonstrated remarkable financial strength with an impressive 88% revenue growth in the last twelve months. According to InvestingPro data, analysts maintain a strong buy consensus on the stock.

The upgrade comes after argenx announced that its drug Vyvgart met the primary endpoint in the Phase 3 ADAPT SERON study for seronegative generalized myasthenia gravis (gMG) patients, demonstrating clinical improvement across all three patient subtypes.

The successful trial results position argenx to file a supplemental Biologics License Application (sBLA) for Vyvgart by the end of 2025, potentially expanding the drug’s reach to approximately 20% of gMG patients classified as seronegative, representing about 11,000 addressable patients in the United States.

Piper Sandler cited multiple growth catalysts for argenx, including the ongoing prefilled syringe launch, continued global expansion efforts, and additional near-term opportunities for label expansions that enhance Vyvgart’s growth potential.

The investment firm maintained argenx as a "top pick," expressing optimism about the company’s outlook for 2025 and beyond, including the maturation of its non-Vyvgart portfolio.

In other recent news, Argenx NV reported robust earnings for Q2 2025, significantly surpassing market expectations. The company achieved an earnings per share of $6.32, more than double the anticipated $3.06, resulting in a 106.54% surprise. Revenue also exceeded forecasts, reaching $1.74 billion compared to the expected $876.3 million, marking a 98.56% surprise. JPMorgan has reiterated an Overweight rating on Argenx, following positive results from the ADAPT SERON trial for Vyvgart in generalized Myasthenia Gravis patients. Oppenheimer also maintained an Outperform rating after Phase 3 trial results showed statistical significance for IV Vyvgart in seronegative myasthenia gravis. RBC Capital echoed this sentiment, reaffirming an Outperform rating and highlighting Vyvgart’s benefits across all antibody status subtypes. Additionally, RBC Capital initiated coverage with an Outperform rating, noting Argenx’s substantial growth since Vyvgart’s initial approval. These developments reflect Argenx’s ongoing success and potential in the treatment landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.